Crossmark

High doses of tigecycline are associated with satisfactory plasmatic and pulmonary concentrations for the treatment of severe infections due to fully susceptible bacteria: do we need even higher doses in patients under CRRT?

Crossref DOI link: https://doi.org/10.1186/s13613-020-00758-5

Published Online: 2020-10-14

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Honore, Patrick M.

Barreto Gutierrez, Leonel

Kugener, Luc

Redant, Sebastien

Attou, Rachid

Gallerani, Andrea

De Bels, David
License Information

Text and Data Mining valid from 2020-10-14

Version of Record valid from 2020-10-14
More Information

Article History

Received: 13 August 2020

Accepted: 6 October 2020

First Online: 14 October 2020

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare to have no competing interests.

Document is current

Any future updates will be listed below